



2022; 12(12): 5335-5336. doi: 10.7150/thno.76351

Erratum

Evaluation of ¹⁸F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration *in vivo* in rodents and in human tissue: Erratum

François-Xavier Lepelletier^{1,2*}, Matthias Vandesquille^{1,2*}, Marie-Claude Asselin^{2,3}, Christian Prenant², Andrew C Robinson⁴, David M A Mann⁴, Michael Green^{2,3}, Elizabeth Barnett^{2,3}, Samuel D Banister⁵, Marco Mottinelli⁶, Christophe Mesangeau⁷, Christopher R McCurdy^{6,8}, Inga B Fricke^{9*}, Andreas H. Jacobs^{9,10}, Michael Kassiou⁵, Hervé Boutin^{1,2^{SI}}

- 1. Faculty of Biology, Medicine and Health, School of Biological Sciences, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, United Kingdom.
- 2. Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom.
- 3. Faculty of Biology, Medicine and Health, School of Health Sciences, Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, United Kingdom.
- 4. Salford Royal NHS Foundation Trust, Department of Clinical & Cognitive Neurosciences, Clinical Sciences Building, Salford, United Kingdom.
- 5. School of Chemistry, The University of Sydney, Sydney, Australia.
- 6. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
- 7. Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
- 8. UF Translational Drug Development Core, University of Florida, Gainesville, FL 32610, USA.
- 9. European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-Universität (WWU), Münster, Germany.
- 10. Department of Geriatrics and Neurology, Johanniter Hospital, Bonn, Germany.

*Current addresses: FXL: Université de Caen Normandie, IUT Grand Ouest Normandie, Département Hygiène Sécurité Environnement, Rue des Noës Davy 14500 Vire-Normandie (E-mail: fx.lepelletier@gmail.com); MV: Institut Européen de Génomique du Diabète, 1 place de Verdun, 59045 Lille, France (E-mail: matthias.vandesquille@univ-lille.fr); IF: Bruker BioSpin MRI GmbH, Rudolf-Plank-Str. 23, 76275 Ettlingen, Germany (E-mail: inga.fricke@bruker.com).

🖂 Corresponding author: Hervé Boutin, Wolfson Molecular Imaging Centre, University of Manchester, 27 Palatine Road, Manchester, M20 3LJ, UK; E-mail: herve.boutin@manchester.ac.uk; Phone: +44 161 275 0078.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Published: 2022.07.08

Corrected article: Theranostics 2020; 10(18): 7938-7955. doi: 10.7150/thno.47585.

The authors regret that the original version of our paper unfortunately contained incorrect data in Figure 2B, where the vertical plot of the ROIs significantly different of the mesencephalic region (x-axis, right hand side of the graph) were incorrect and did not match the horizontal level of significant differences. The correct version of the Figure 2B is shown below.

The corrections made in this erratum do not affect the original conclusions. The authors apologize for any inconvenience that the errors may have caused.



Figure 2: (A) Average uptake (from sum-image 20-60min post-injection) of ¹⁸F-IAM6067 in different brain regions in rats (n=8, data are expressed as SUV mean ± SD). (B) Heat map of the adjusted P values (Sidak's post-hoc test) showing all the comparisons between the various brain regions for ¹⁸F-IAM6067 uptake. Non-significant differences are shown in blue. (C) PET sum-image (20-60min) co-registered with CT showing ¹⁸F-IAM6067 uptake with hippocampus, thalamus medio-dorsal, frontoparietal somatosensory cortex and amygdala highlighted by dotted lines.